Relationship between vascular endothelial growth factor and macular edema in retinal vein branch obstruction

Figures & data

Table 1 Characteristics of the BRVO before intravitreal ranibizumab administration

Comparison item	BRVO (n=19)
Age (years)	71.05±9.05
Sex distribution	M 13, F 6
BCVA (LogMAR)	0.52±0.48
Flare (pc/ms)	8.19±3.61
VEGF (pg/mL)	188.78±219.91
CRT (μm)	509.26±130.93

Abbreviations: BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; F, female; M, male.

Table 2 Correlation between VEGF and flare, CRT, and BCVA prior to intravitreal ranibizumab administration

Item of correlation	Coefficient of correlation with VEGF	P-value
Flare	0.5	0.03
CRT	0.11	0.65
BCVA	0.4	0.09

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; VEGF, vascular endothelial growth factor.

Figure 1 A correlation between VEGF concentration and flare preoperatively, as shown by the single regression line (y=30.3x−59.1).

Abbreviation: VEGF, vascular endothelial growth factor.

Figure 2 Time course of BCVA changes after IVR.

Note: The improvement was significant for all time points after IVR, as compared with before IVR.
Abbreviations: BCVA, best-corrected visual acuity; IVR, intravitreal ranibizumab.

Figure 3 Time course of flare changes after IVR treatment.

Note: The improvement was significant for all time points after IVR, as compared with before IVR.
Abbreviation: IVR, intravitreal ranibizumab.

Figure 4 Time course of changes in CRT at the fovea after IVR treatment.

Note: The improvement was significant for all time points after IVR, as compared with before IVR.
Abbreviations: CRT, central retinal thickness; IVR, intravitreal ranibizumab.

Table 3 The changes in VEGF, CRT, and flare values at the additional IVR

	VEGF (pg/mL)		CRT (μm)		Flare (pc/ms)
	Pre	Post	Pre	Post	Pre	Post
Case 1	22.18	26.85	574	438	5.6	5.4
Case 2	456.87	391.43	390	535	11.6	8.7
Case 3	96.96	148.38	460	452	5.1	5.4
Case 4	36.2	54.89	521	331	7.6	4.9
Case 5	41.91	45.55	413	468	6.1	4.4
Case 6	50.22	0	377	407	6.3	6
Case 7	120.33	26.85	622	369	17.5	7.6

Abbreviations: CRT, central retinal thickness; IVR, intravitreal ranibizumab; pre, preintravitreal ranibizumab; post, postintravitreal ranibizumab; VEGF, vascular endothelial growth factor.

Table 4 Correlation between VEGF and CRT or flare at the time of additional IVR treatment

Item of correlation	Coefficient of correlation with VEGF	P-value
Flare	0.65	0.12
CRT	0.73	0.06

Abbreviations: CRT, central retinal thickness; IVR, intravitreal ranibizumab; VEGF, vascular endothelial growth factor.